Presidential Actions

Memorandum for the Secretary of Health and Human Services the Commissioner of Food and Drugs

SignedSeptember 9, 2025
Memorandum·Donald Trump·Drug Advertising
Why This Matters

The FDA will require drug companies to provide more information about the risks of prescription drugs in their advertisements. This change aims to ensure that ads present a fair balance of both benefits and risks.

Consumers will see more detailed information about potential side effects and risks in drug advertisements, helping them make more informed decisions.
Consumers of prescription drugs and pharmaceutical companies that advertise directly to the public.
Summary

1. The FDA will increase scrutiny on how drug companies present information in their ads, particularly in broadcast media. 2. Historically, drug advertisements have been allowed to include less information, leading to potential misunderstandings about drug safety. 3. This memorandum emphasizes the importance of maintaining the physician-patient relationship by ensuring that ads do not promote medications over necessary lifestyle changes.

Who is affected?

Consumers of prescription drugs and pharmaceutical companies that advertise directly to the public.

Read on WhiteHouse.govwhitehouse.gov
Read Full Text

MEMORANDUM FOR THE SECRETARY OF HEALTH AND HUMAN SERVICES THE COMMISSIONER OF FOOD AND DRUGS

SUBJECT:       Addressing Misleading Direct-To-Consumer

               Prescription Drug Advertisements

In 1962, the Congress vested the Food and Drug Administration (FDA) with the authority to regulate prescription drug advertising.  These advertisements can mislead the public about the risks and benefits, encourage medications over lifestyle changes, inappropriately intervene in the physician-patient relationship, and advantage expensive drugs over cheaper generics.

The FDA has historically stipulated that a manufacturer, packer, or distributor must provide the public with materially complete information that fairly balances both the benefits and the risks of the drug.  Over time, however, the FDA’s requirements have permitted drug companies to include less information, particularly in broadcast advertising, and drug manufacturer advertising has skyrocketed in recent decades.

My Administration will ensure that the current regulatory framework for drug advertising results in fair, balanced, and complete information for American consumers. 

The Secretary of Health and Human Services shall therefore take appropriate action to ensure transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug advertisements, to the extent permitted by applicable law.  The Commissioner of Food and Drugs shall take appropriate action to enforce the Federal Food, Drug, and Cosmetic Act’s prescription drug advertising provisions, and otherwise ensure truthful and non-misleading information in direct-to-consumer prescription drug advertisements.  

This memorandum is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.

                               DONALD J. TRUMP

Memorandum for the Secretary of Health and Human Services the Commissioner of Food and Drugs - PILLARS